EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-SA 4.0

A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma

Fenghong Zhang, Yu Chen, Dongping Huang, Suning Chen

Indian Journal of Pathology and Microbiology · 2025

DOI: 10.4103/ijpm.ijpm_990_23 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Indian Journal of Pathology and Microbiology, 2025. Verfasst von Fenghong Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soo…. Hauptthemen laut MEDLINE: Thrombocythemia, Essential, Janus Kinase 2, Colorectal Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM), essential thrombocythemia (ET), and colorectal adenocarcinoma (CA) are three distinct diseases. The co-occurrence of MM, ET, and CA in a single patient is exceedingly rare. Our study presents a remarkable case involving a 75-year-old patient who was simultaneously diagnosed with these three diseases. The JAK2V617F mutation was detected in the bone marrow with a variant allele frequency (VAF) of 13.38%, whereas the isolated CD138-positive plasma cells exhibited a significantly lower VAF of 0.38%. This notable difference implies the potential for separate origins of MM and ET. Additionally, the patient responded well to a bortezomib-based treatment regimen, despite the absence of specific therapy for ET. We believe that our findings add new understanding to these rare diseases and encourage further research in this area.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombocythemia, EssentialJanus Kinase 2Colorectal NeoplasmsAdenocarcinomaMultiple MyelomaHumansAgedMaleBone MarrowBortezomibAntineoplastic AgentsTreatment Outcome

Stichwörter der Autor:innen

Colorectal adenocarcinomaJAK2V617Fessential thrombocythemiamultiple myeloma

Substanzen

Janus Kinase 2JAK2 protein, humanBortezomibAntineoplastic Agents

Autor:innen und Institutionen

  • National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P. R. China.
  • Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, P. R. China.
  • Department of Hematology, the Second Affiliated Hospital of Wannan Medical College, Wuhu, People's Republic of China Wannan Medical College, Wuhu, Anhui, P. R. China.
  • Department of Hematology, the First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, P. R. China.

Zitieren

APA

Zhang, F., Chen, Y., Huang, D., & Chen, S. (2025). A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma. Indian Journal of Pathology and Microbiology. https://doi.org/10.4103/ijpm.ijpm_990_23

Vancouver

Zhang F, Chen Y, Huang D, Chen S. A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma. Indian Journal of Pathology and Microbiology. 2025. doi:10.4103/ijpm.ijpm_990_23

BibTeX
@article{Zhang2025,
  author = {Zhang, Fenghong and Chen, Yu and Huang, Dongping and Chen, Suning},
  title = {A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma},
  journal = {Indian Journal of Pathology and Microbiology},
  year = {2025},
  doi = {10.4103/ijpm.ijpm_990_23}
}
Kostenlos starten →